<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Emerg Infect Dis</journal-id>
      <journal-id journal-id-type="iso-abbrev">Emerging Infect. Dis</journal-id>
      <journal-id journal-id-type="publisher-id">EID</journal-id>
      <journal-title-group>
        <journal-title>Emerging Infectious Diseases</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1080-6040</issn>
      <issn pub-type="epub">1080-6059</issn>
      <publisher>
        <publisher-name>Centers for Disease Control and Prevention</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">22305185</article-id>
      <article-id pub-id-type="pmc">3365615</article-id>
      <article-id pub-id-type="publisher-id">11-1479</article-id>
      <article-id pub-id-type="doi">10.3201/eid1802.111479</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Dispatch</subject>
        </subj-group>
        <subj-group subj-group-type="article-type">
          <subject>Dispatch</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Multiorgan Dysfunction Caused by Travel-associated African
Trypanosomiasis</article-title>
        <alt-title alt-title-type="running-head">Travel-associated African
Trypanosomiasis</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Cottle</surname>
            <given-names>Lucy E.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Peters</surname>
            <given-names>Joanna R.</given-names>
          </name>
          <xref ref-type="fn" rid="FN1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hall</surname>
            <given-names>Alison</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bailey</surname>
            <given-names>J. Wendi</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Noyes</surname>
            <given-names>Harry A.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rimington</surname>
            <given-names>Jane E.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Beeching</surname>
            <given-names>Nicholas J.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Squire</surname>
            <given-names>S. Bertel</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Beadsworth</surname>
            <given-names>Mike B.J.</given-names>
          </name>
        </contrib>
        <aff id="aff1">Royal Liverpool University Hospital, Liverpool, UK (L.E. Cottle, J.R.
Peters, A. Hall, N.J. Beeching, S.B. Squire, M.B.J. Beadsworth);</aff>
        <aff id="aff2">Liverpool School of Tropical Medicine, Liverpool (J.W. Bailey, N.J.
Beeching, S.B. Squire, M.B.J. Beadsworth);</aff>
        <aff id="aff3">University of Liverpool, Liverpool (H.A. Noyes);</aff>
        <aff id="aff4">Hawkshead Medical Practice, Ambleside, UK (J.E. Rimington)</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Address for correspondence: Lucy E. Cottle, Specialist Registrar
in Infectious Diseases, Tropical and Infectious Disease Unit, Royal Liverpool
University Hospital, Prescot St, Liverpool L7 8XP, UK; email: <email xlink:href="lucy.cottle@rlbuht.nhs.uk">lucy.cottle@rlbuht.nhs.uk</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>2</month>
        <year>2012</year>
      </pub-date>
      <volume>18</volume>
      <issue>2</issue>
      <fpage>287</fpage>
      <lpage>289</lpage>
      <abstract>
        <p>We describe a case of multiorgan dysfunction secondary to <italic>Trypanosoma
brucei</italic>
<italic>rhodesiense</italic> infection acquired on safari in Zambia. This case
was one of several recently reported to ProMED-mail in persons who had traveled
to this region. Trypanosomiasis remains rare in travelers but should be
considered in febrile patients who have returned from trypanosomiasis-endemic
areas of Africa.</p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <title>Keywords: </title>
        <kwd>Trypanosomiasis</kwd>
        <kwd>African</kwd>
        <kwd>African sleeping sickness</kwd>
        <kwd>trypanosomes</kwd>
        <kwd>parasites</kwd>
        <kwd>trypanocidal agents</kwd>
        <kwd>suramin</kwd>
        <kwd>adverse drug reaction</kwd>
        <kwd>drug toxicity</kwd>
        <kwd>tsetse fly</kwd>
        <kwd>
          <italic>Trypanosoma brucei rhodesiense</italic>
        </kwd>
        <kwd>multi-organ dysfunction</kwd>
        <kwd>travel</kwd>
        <kwd>Zambia</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>We describe a British safari tourist with multi-organ dysfunction and shock secondary to
African trypanosomiasis. This case illustrates the complications associated with
treatment of <italic>Trypanosoma brucei rhodesiense</italic> infection and highlights a
recent increase in cases reported to ProMED (<ext-link ext-link-type="uri" xlink:href="http://www.promedmail.org">www.promedmail.org</ext-link>) of
trypanosomiasis in travelers to Zambia.</p>
    <sec>
      <title>The Case-Patient</title>
      <p>A 49-year-old woman with a 5-day history of fever, malaise, headache, dizziness,
abdominal discomfort, diarrhea, and vomiting sought treatment 1 day after returning
to the United Kingdom from a 2-week safari in Zambia. During the safari, she spent 3
days in the South Luangwa National Park, 3 days in the Lower Zambezi National Park,
and 6 days in Kafue National Park. Initial blood films examined at Furness General
Hospital were negative for malaria parasites but positive for trypanosomes. Urgent
transfer of the patient to the Tropical and Infectious Disease Unit in Liverpool,
UK, was arranged.</p>
      <p>Upon arrival, the patient was dehydrated and had jaundice and tachycardia, but she
initially was normotensive. Examination revealed reduced breath sounds at the lung
bases and a distended, nontender abdomen. There was a mild erythematous rash on the
patient&#x2019;s abdomen, but no chancres. Results of a neurologic examination were
unremarkable.</p>
      <p>Repeat blood films confirmed numerous trypanosomes (<xref ref-type="fig" rid="F1">Figure</xref>), which, given the patient&#x2019;s travel history, were
considered likely to be <italic>T. b. rhodesiense</italic>. PCR results confirmed
the trypanosomes positive for the <italic>T. b. rhodesiense</italic>&#x2013;specific
serum resistance&#x2013;associated gene (<xref ref-type="bibr" rid="R1"><italic>1</italic></xref>). Blood test results were as follows: urea 9.2
mmol/L, creatinine 146 &#x3BC;mol/L, leukocytes 3.7 &#xD7; 10<sup>9</sup>
cells/L, platelets 13 &#xD7; 10<sup>9</sup>/L, C-reactive protein 234 mg/L,
alanine aminotransferase 179 U/L, bilirubin 38 &#x3BC;mol/L, and prothrombin time
13.5 s.</p>
      <fig id="F1" fig-type="figure" position="float">
        <label>Figure</label>
        <caption>
          <p>Thick film using Field&#x2019;s stain showing trypanosomes under &#xD7;400
magnification. Motile trypanosomes are shown in the <xref ref-type="other" rid="vid1">Video</xref>.</p>
        </caption>
        <graphic xlink:href="11-1479-F1"/>
      </fig>
      <fig id="vid1" fig-type="video" position="float">
        <label>Video</label>
        <caption>
          <p>Motile trypanosomes. </p>
        </caption>
        <p content-type="vlink">Direct Video Link: <ext-link ext-link-type="uri" xlink:href="http://streaming.cdc.gov/vod.php?id=7e517b3f1a94f72aad563c8c5d8ceec720120120160142637">http://streaming.cdc.gov/vod.php?id=7e517b3f1a94f72aad563c8c5d8ceec720120120160142637</ext-link></p>
        <graphic xlink:href="11-1479-vid1"/>
        <media xlink:href="11-1479-vid1.wmv" xlink:type="simple" id="d34e221" position="anchor" mimetype="video" mime-subtype="x-ms-wmv"/>
      </fig>
      <p>Despite fluid resuscitation, the patient became increasingly hypotensive over the
next 12 hours, prompting transfer to the intensive care unit. A 100-mg test dose of
suramin was well tolerated by the patient; however, the first full treatment dose
was complicated by circulatory collapse and bronchoconstriction, which required
administration of hydrocortisone and chlorphenamine and immediate discontinuation of
the suramin infusion. Subsequent investigation showed that the suramin dose had been
infused more rapidly than prescribed. Further doses administered as slow infusions
were uncomplicated.</p>
      <p>Hypotension persisted for 4 days but did not necessitate vasopressors. Results of a
short synacthen test, electrocardiogram, and echocardiogram were normal.</p>
      <p>After the patient received 2 treatment doses of suramin and analysis of repeat blood
films confirmed that parasitemia had cleared, a lumbar puncture was performed. The
cerebrospinal fluid (CSF) had 4 leukocytes/&#x3BC;L and normal levels of protein
and glucose, and no trypanosomes were detected after double centrifugation.</p>
      <p>The patient received a full course of suramin for early-stage disease, (regimen in
<xref ref-type="table" rid="T1">Table 1</xref>), which resulted in full
recovery. As follow-up care, the patient will receive repeat lumbar punctures every
3 months for 2 years to exclude occult invasion of the central nervous system (CNS).
Thus far, 3 repeat lumbar punctures have shown no evidence of CNS invasion.</p>
      <table-wrap id="T1" position="float">
        <label>Table 1</label>
        <caption>
          <title>Treatment regimen for <italic>Trypanosoma brucei rhodesiense</italic>
infection in adults*</title>
        </caption>
        <table frame="hsides" rules="groups">
          <col width="41" span="1"/>
          <col width="67" span="1"/>
          <col width="193" span="1"/>
          <col width="180" span="1"/>
          <thead>
            <tr>
              <th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Disease stage</th>
              <th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Drug, route of
administration</th>
              <th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Regimen</th>
              <th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Adverse effects</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" align="left" scope="row" rowspan="1" colspan="1">First</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Suramin, intravenous</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Test dose of 100 mg in 100 mL 0.9%
saline over 30 min on day 0; and 5 doses of 20 mg/kg (maximum 1
g/dose) in 250 mL 0.9% saline over 3 h on days 1, 3, 7, 14, 21</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Hypersensitivity reactions (early and
late); nephrotoxicity, hepatotoxicity, hemolytic anemia, peripheral
neuropathy, agranulocytosis, thrombocytopenia, and cutaneous
reactions</td>
            </tr>
            <tr>
              <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Second</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Melarsoprol, intravenous</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.0&#x2013;3.6 mg/kg/d (maximum 180
mg/d) for 3 d; after 7 d, 3.6 mg/kg/d for 3 d; after 7 more d, 3.6
mg/kg/d for 3 d&#x2020;</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Encephalopathy, cutaneous reactions,
peripheral neuropathy, cardiac arrhythmias, thrombophlebitis, fever,
and gastric upset</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p>*Source of drug regimen: Brun et al. (<xref ref-type="bibr" rid="R2"><italic>2</italic></xref>) and Abramowicz (<xref ref-type="bibr" rid="R3"><italic>3</italic></xref>).&#x2028;&#x2020;In frail patients,
begin with 18 mg melarsoprol and progressively increase dose (<xref ref-type="bibr" rid="R3"><italic>3</italic></xref>). Pretreatment with
suramin for 2&#x2013;4 d is recommended for debilitated patients.</p>
        </table-wrap-foot>
      </table-wrap>
      <p>African trypanosomiasis is caused by the protozoan parasite <italic>T.
brucei</italic>, which is transmitted by tsetse flies. Two subspecies are
pathogenic in humans: <italic>T. b. gambiense</italic> in central and western
Africa, and <italic>T. b. rhodesiense</italic> in eastern and southern Africa.</p>
      <p>Disease progresses in 2 stages. In the first stage, parasites spread in the blood to
the lymph nodes, liver, spleen, heart, endocrine system, and eyes (<xref ref-type="bibr" rid="R4"><italic>4</italic></xref>). Untreated, they invade the
CNS, which leads to second-stage or meningoencephalitic disease with characteristic
sleep disturbances. Progression to the second stage may take months in <italic>T. b.
gambiense</italic> infection but only weeks in <italic>T. b.
rhodesiense</italic> infection.</p>
      <p>Although trypanosomiasis is uncommon in travelers, it should be considered in the
differential diagnosis of patients with fever who have returned from
trypanosomiasis-endemic areas of Africa (<xref ref-type="bibr" rid="R5"><italic>5</italic></xref>). Recent reports suggest an increase in cases
emerging from Zambia, particularly from the South Luangwa Valley (<xref ref-type="table" rid="T2">Table 2</xref>) (<xref ref-type="bibr" rid="R6"><italic>6</italic></xref>). Whether these cases reflect an increased risk
for infection in that region or increasing tourism in a trypanosomiasis-endemic area
is unclear. Infection in travelers is usually characterized by an acute febrile
illness, sometimes associated with a macular evanescent rash or chancre (<xref ref-type="bibr" rid="R2"><italic>2</italic></xref><italic>,</italic><xref ref-type="bibr" rid="R4"><italic>4</italic></xref>). Laboratory tests often
indicate anemia, thrombocytopenia, leukopenia, impaired renal function, electrolyte
disturbances, coagulation abnormalities, and elevation in hepatic transaminase and
C-reactive protein levels (<xref ref-type="bibr" rid="R2"><italic>2</italic></xref><italic>,</italic><xref ref-type="bibr" rid="R7"><italic>7</italic></xref>).</p>
      <table-wrap id="T2" position="float">
        <label>Table 2</label>
        <caption>
          <title>Reports to ProMED-mail of <italic>Trypanosoma brucei rhodesiense</italic>
infections associated with travel to or bordering Zambia, 2010*</title>
        </caption>
        <table frame="hsides" rules="groups">
          <col width="61" span="1"/>
          <col width="103" span="1"/>
          <col width="94" span="1"/>
          <col width="90" span="1"/>
          <col width="133" span="1"/>
          <thead>
            <tr>
              <th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Month of report</th>
              <th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">ProMED-mail archive
no.</th>
              <th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Nationality of
patient</th>
              <th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Travel activity</th>
              <th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Area visited</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" align="left" scope="row" rowspan="1" colspan="1">September</td>
              <td valign="top" align="center" rowspan="1" colspan="1">20100915.3338</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Zambian</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Visiting game ranch</td>
              <td valign="top" align="center" rowspan="1" colspan="1">South Luangwa Valley, Zambia</td>
            </tr>
            <tr>
              <td valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">20100915.3338</td>
              <td valign="top" align="center" rowspan="1" colspan="1">American</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Hunting safari</td>
              <td valign="top" align="center" rowspan="1" colspan="1">South Luangwa Valley, Zambia</td>
            </tr>
            <tr>
              <td valign="top" align="left" scope="row" rowspan="1" colspan="1">October&#x2020;</td>
              <td valign="top" align="center" rowspan="1" colspan="1">20101022.3833</td>
              <td valign="top" align="center" rowspan="1" colspan="1">British</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Camping safari</td>
              <td valign="top" align="center" rowspan="1" colspan="1">South Luangwa National Park, Lower
Zambez National Park, Kafu National Park, Zambia</td>
            </tr>
            <tr>
              <td valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">20101022.3833</td>
              <td valign="top" align="center" rowspan="1" colspan="1">British</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Visiting national park</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Mana Pool National Park, Zimbabwe
(bordering Zambia)</td>
            </tr>
            <tr>
              <td valign="top" align="left" scope="row" rowspan="1" colspan="1">November</td>
              <td valign="top" align="center" rowspan="1" colspan="1">20101111.4093</td>
              <td valign="top" align="center" rowspan="1" colspan="1">South African national of Scandinavian
origin</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Hiking</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Luangwa River area, Zambia</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p>*Reports in (<xref ref-type="bibr" rid="R6"><italic>6</italic></xref>). Since
the start of 2005, 11 other cases of <italic>T. b. rhodesiense</italic>
infection in travelers have been reported in ProMED-mail; those cases were
acquired in Uganda (1), Tanzania (3), and Malawi (7).&#x2028;&#x2020;Case
presented in this report.</p>
        </table-wrap-foot>
      </table-wrap>
      <p>Conditions that should be considered in patients with persistent hypotension are
adrenal insufficiency and cardiac dysfunction. The prevalence of adrenal
insufficiency was 27% in a study of Ugandan patients with trypanosomiasis (<xref ref-type="bibr" rid="R8"><italic>8</italic></xref>). Myocarditis, pericarditis,
and congestive cardiac failure have been described and should be excluded by
electrocardiogram and echocardiography (<xref ref-type="bibr" rid="R4"><italic>4</italic></xref>).</p>
      <p>The treatment for first-stage <italic>T. b. rhodesiense</italic> infection is
intravenous suramin, given as 5 injections of 20 mg/kg each over 3&#x2013;4 weeks
(<xref ref-type="bibr" rid="R2"><italic>2</italic></xref><italic>,</italic><xref ref-type="bibr" rid="R4"><italic>4</italic></xref>). Early hypersensitivity
reactions to suramin (i.e., nausea, circulatory collapse, and urticaria) are
described in 0.1%&#x2013;0.3% of patients; thus, an initial test dose is advocated
(<xref ref-type="bibr" rid="R9"><italic>9</italic></xref>).</p>
      <p>Second-stage <italic>T. b. rhodesiense</italic> infection is treated with
melarsoprol, a highly toxic arsenical which causes a severe reactive encephalopathy
in &#x2248;10% of patients, half of whom die as a result (<xref ref-type="bibr" rid="R10"><italic>10</italic></xref>). This toxicity among patients emphasizes
the importance of accurate staging, which is determined by CSF examination.
According to World Health Organization guidelines, the presence of &gt;5
leukocytes/&#x3BC;L and/or the presence of trypanosomes in the CSF indicates
second-stage disease (<xref ref-type="bibr" rid="R11"><italic>11</italic></xref>).
Lumbar puncture should be deferred until clearance of blood parasitemia has been
confirmed.</p>
      <p>In view of our patient&#x2019;s rapid onset of a high level of parasitemia, we
investigated the possibility of a genetic susceptibility to trypanosomal infection.
Human plasma contains a trypanosome lytic factor called apolipoprotein L-1 (APOL1)
(<xref ref-type="bibr" rid="R12"><italic>12</italic></xref>). This protein
causes lysis of <italic>T. brucei</italic> subspecies other than
<italic>rhodesiense</italic> and <italic>gambiense,</italic> both of which have
acquired resistance to it (<xref ref-type="bibr" rid="R13"><italic>13</italic></xref>). In 2006, Vanhollebeke et al. (<xref ref-type="bibr" rid="R14"><italic>14</italic></xref>) described a patient
infected with <italic>T. evansi</italic>, which is usually sensitive to APOL1. The
patient&#x2019;s serum lacked APOL1 due to mutations in the <italic>APOL1</italic>
gene, rendering him susceptible to a species regarded as nonpathogenic in humans. We
sequenced the <italic>APOL1</italic> gene of our patient, but no substantial
variations suggesting enhanced susceptibility were detected.</p>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusions</title>
      <p>In summary, trypanosomiasis remains rare in travelers, but possible infection should
be considered in patients with fever who have returned from trypanosomiasis-endemic
areas of Africa. Early reporting of trypanosomiasis cases to ProMED-mail allows
timely recognition of emerging safari destinations that present an increased risk
for infection to travelers. In patients with <italic>T. b. rhodesiense</italic>
infection, multi-organ dysfunction may develop in early-stage disease. Treatment of
such cases should be managed with critical care support, and it should be remembered
that rapid infusion of suramin may precipitate circulatory collapse.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="citation">
        <p><italic>Suggested citation for this article</italic>: Cottle LE, Peters JR, Hall
A, Bailey JW, Noyes HA, Rimington JE. Multiorgan dysfunction caused by
travel-associated African trypanosomiasis. Emerg Infect Dis [serial on the
Internet]. 2012 Feb [<italic>date cited</italic>]. Epub 2012 Jan 4. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3201/eid1802.111479">http://dx.doi.org/10.3201/eid1802.111479</ext-link></p>
      </fn>
      <fn id="FN1">
        <label>1</label>
        <p>Current affiliation: Worthing Hospital, Worthing, UK.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgments</title>
      <p>We acknowledge Anthony Macheta from Furness General Hospital.</p>
    </ack>
    <bio id="d34e542">
      <p>Dr Cottle is a specialist registrar in infectious diseases at the Tropical and
Infectious Disease Unit in Liverpool, UK.</p>
    </bio>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Welburn</surname>
<given-names>SC</given-names></string-name>,
<string-name><surname>Picozzi</surname>
<given-names>K</given-names></string-name>,
<string-name><surname>F&#xE8;vre</surname>
<given-names>EM</given-names></string-name>,
<string-name><surname>Coleman</surname>
<given-names>PG</given-names></string-name>,
<string-name><surname>Odiit</surname>
<given-names>M</given-names></string-name>,
<string-name><surname>Carrington</surname>
<given-names>M</given-names></string-name>, <etal/>
<article-title>Identification of human-infective trypanosomes in animal
reservoir of sleeping sickness in Uganda by means of
serum-resistance-associated (SRA) gene.</article-title>
<source>Lancet</source>.
<year>2001</year>;<volume>358</volume>:<fpage>2017</fpage>&#x2013;<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(01)07096-9</pub-id><pub-id pub-id-type="pmid">11755607</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Brun</surname>
<given-names>R</given-names></string-name>,
<string-name><surname>Blum</surname>
<given-names>J</given-names></string-name>,
<string-name><surname>Chappuis</surname>
<given-names>F</given-names></string-name>,
<string-name><surname>Burri</surname>
<given-names>C</given-names></string-name>
<article-title>Human African
trypanosomiasis.</article-title>
<source>Lancet</source>.
<year>2010</year>;<volume>375</volume>:<fpage>148</fpage>&#x2013;<lpage>59</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(09)60829-1</pub-id><pub-id pub-id-type="pmid">19833383</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3. </label>
        <mixed-citation publication-type="book"><string-name><surname>Abramowicz</surname>
<given-names>M</given-names></string-name> Drugs for parasitic infections.
In: Abramowicz M, editor. The medical letter on drugs and therapeutics. New
Rochelle (NY): The Medical Letter, Inc; <year>2000</year> p.
1&#x2013;12.</mixed-citation>
      </ref>
      <ref id="R4">
        <label>4. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Kennedy</surname>
<given-names>PG</given-names></string-name>
<article-title>The continuing
problem of human African trypanosomiasis (sleeping
sickness).</article-title>
<source>Ann Neurol</source>.
<year>2008</year>;<volume>64</volume>:<fpage>116</fpage>&#x2013;<lpage>26</lpage>
<pub-id pub-id-type="doi">10.1002/ana.21429</pub-id><pub-id pub-id-type="pmid">18756506</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Gautret</surname>
<given-names>P</given-names></string-name>,
<string-name><surname>Clerinx</surname>
<given-names>J</given-names></string-name>,
<string-name><surname>Caumes</surname>
<given-names>E</given-names></string-name>,
<string-name><surname>Simon</surname>
<given-names>F</given-names></string-name>,
<string-name><surname>Jensenius</surname>
<given-names>M</given-names></string-name>,
<string-name><surname>Loutan</surname>
<given-names>L</given-names></string-name>, <etal/>
<article-title>Imported human African trypanosomiasis in Europe,
2005&#x2013;2009.</article-title>
<source>Euro Surveill</source>. <year>2009</year>;<volume>14</volume>:pii:19327.
<pub-id pub-id-type="pmid">19758542</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6. </label>
        <mixed-citation publication-type="webpage"><collab>ProMED-mail</collab> Archive nos.
20100915.3338, 20101022.3833, and 20101111.4093 [cited 2011 Sep 22]. <ext-link ext-link-type="uri" xlink:href="http://www.promedmail.org">http://www.promedmail.org</ext-link></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Sinha</surname>
<given-names>A</given-names></string-name>,
<string-name><surname>Grace</surname>
<given-names>C</given-names></string-name>,
<string-name><surname>Alston</surname>
<given-names>WK</given-names></string-name>,
<string-name><surname>Westenfeld</surname>
<given-names>F</given-names></string-name>,
<string-name><surname>Maguire</surname>
<given-names>JH</given-names></string-name>
<article-title>African
trypanosomiasis in two travelers from the United States.</article-title>
<source>Clin Infect Dis</source>.
<year>1999</year>;<volume>29</volume>:<fpage>840</fpage>&#x2013;<lpage>4</lpage>
<pub-id pub-id-type="doi">10.1086/520446</pub-id><pub-id pub-id-type="pmid">10589900</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Reincke</surname>
<given-names>M</given-names></string-name>,
<string-name><surname>Arlt</surname>
<given-names>W</given-names></string-name>,
<string-name><surname>Heppner</surname>
<given-names>C</given-names></string-name>,
<string-name><surname>Petzke</surname>
<given-names>F</given-names></string-name>,
<string-name><surname>Chrousos</surname>
<given-names>GP</given-names></string-name>,
<string-name><surname>Allolio</surname>
<given-names>B</given-names></string-name>
<article-title>Neuroendocrine
dysfunction in African trypanosomiasis.</article-title>
<source>Ann N Y Acad Sci</source>.
<year>1998</year>;<volume>840</volume>:<fpage>809</fpage>&#x2013;<lpage>21</lpage>
<pub-id pub-id-type="doi">10.1111/j.1749-6632.1998.tb09619.x</pub-id><pub-id pub-id-type="pmid">9629307</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Burri</surname>
<given-names>C</given-names></string-name>
<article-title>Chemotherapy
against human African trypanosomiasis: is there a road to
success?</article-title>
<source>Parasitology</source>.
<year>2010</year>;<volume>137</volume>:<fpage>1987</fpage>&#x2013;<lpage>94</lpage>
<pub-id pub-id-type="doi">10.1017/S0031182010001137</pub-id><pub-id pub-id-type="pmid">20961469</pub-id></mixed-citation>
      </ref>
      <ref id="R10">
        <label>10. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Rodgers</surname>
<given-names>J</given-names></string-name>
<article-title>Human African
trypanosomiasis, chemotherapy and CNS disease.</article-title>
<source>J Neuroimmunol</source>.
<year>2009</year>;<volume>211</volume>:<fpage>16</fpage>&#x2013;<lpage>22</lpage>
<pub-id pub-id-type="doi">10.1016/j.jneuroim.2009.02.007</pub-id><pub-id pub-id-type="pmid">19269696</pub-id></mixed-citation>
      </ref>
      <ref id="R11">
        <label>11. </label>
        <mixed-citation publication-type="other"><collab>World Health Organization</collab> Control
and surveillance of African trypanosomiasis. Report of a WHO expert committee.
WHO Technical Report Series. <year>1998</year>;881:I&#x2013;VI,
1&#x2013;114.</mixed-citation>
      </ref>
      <ref id="R12">
        <label>12. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Vanhamme</surname>
<given-names>L</given-names></string-name>,
<string-name><surname>Paturiaux-Hanocq</surname>
<given-names>F</given-names></string-name>,
<string-name><surname>Poelvoorde</surname>
<given-names>P</given-names></string-name>,
<string-name><surname>Nolan</surname>
<given-names>DP</given-names></string-name>,
<string-name><surname>Lins</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Van Den
Abbeele</surname>
<given-names>J</given-names></string-name>, <etal/>
<article-title>Apolipoprotein L&#x2013;I is the trypanosome lytic factor of
human serum.</article-title>
<source>Nature</source>.
<year>2003</year>;<volume>422</volume>:<fpage>83</fpage>&#x2013;<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1038/nature01461</pub-id><pub-id pub-id-type="pmid">12621437</pub-id></mixed-citation>
      </ref>
      <ref id="R13">
        <label>13. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Pays</surname>
<given-names>E</given-names></string-name>,
<string-name><surname>Vanhollebeke</surname>
<given-names>B</given-names></string-name>
<article-title>Human innate
immunity against African trypanosomes.</article-title>
<source>Curr Opin Immunol</source>.
<year>2009</year>;<volume>21</volume>:<fpage>493</fpage>&#x2013;<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1016/j.coi.2009.05.024</pub-id><pub-id pub-id-type="pmid">19559585</pub-id></mixed-citation>
      </ref>
      <ref id="R14">
        <label>14. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Vanhollebeke</surname>
<given-names>B</given-names></string-name>,
<string-name><surname>Truc</surname>
<given-names>P</given-names></string-name>,
<string-name><surname>Poelvoorde</surname>
<given-names>P</given-names></string-name>,
<string-name><surname>Pays</surname>
<given-names>A</given-names></string-name>,
<string-name><surname>Joshi</surname>
<given-names>PP</given-names></string-name>,
<string-name><surname>Katti</surname>
<given-names>R</given-names></string-name>, <etal/>
<article-title>Human <italic>Trypanosoma evansi</italic> infection linked to a
lack of apolipoprotein L&#x2013;I.</article-title>
<source>N Engl J Med</source>.
<year>2006</year>;<volume>355</volume>:<fpage>2752</fpage>&#x2013;<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa063265</pub-id><pub-id pub-id-type="pmid">17192540</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
